

February 25, 2015

Announcement of the receipt of a milestone payment associated
with the commencement of a Phase III clinical trial
of the cancer-specific peptide vaccine S-588410

OncoTherapy Science, Inc. (President & CEO: Masaharu Mori; hereinafter, “OncoTherapy”) announces that Shionogi & Co., Ltd. (Head office: Chuo-ku, Osaka, President and CEO: Isao Teshirogi, hereinafter “Shionogi”) has submitted to Pharmaceuticals and Medical Devices Agency (PMDA), Japan, a clinical trial notification for a Phase III clinical trial of the cancer-specific peptide vaccine S-588410, which OncoTherapy has out-licensed to Shionogi, for esophageal cancer.

The clinical trial is a double-blind comparative Phase III study of S-588410 as adjuvant therapy for esophageal cancer. OncoTherapy will receive a milestone payment from Shionogi in connection with the submission of the clinical trial notification, under the Agreement between both parties announced on February 23, 2015.